Monday, December 21, 2009

Don Wilson, CEO of Endacea, To Lead Regional Innovation Economic Forum At November 6, 2008

Don Wilson, the CEO of Endacea, Inc., an arising RTP biopharmaceutical aggregation affianced in developing proprietary A1 adenosine receptor antagonists as drugs for asthma, sepsis, and biodefense, will advance allotment of the altercation at the November 6, 2008, RTP Tech Event at Goodnight’s.

Endacea has been developing articles based on discoveries fabricated by Constance N. Wilson, M.D. Dr. Wilson is Endacea's Founder and Chief Scientific Officer and the artist of its purinoceptor-based technologies. Her analysis has focused on the role of adenosine receptors and P2X purinoceptors in a advanced ambit of diseases. With a accommodation from the N.C. Biotechnology Center, abutment from angel investors, and a alternation of grants from the National Institutes of Health, Endacea has approved ameliorative ability for the Company’s advance compound, L-97-1: 1) above to that of Merck’s Singulair® in a aerial archetypal of allergic asthma, 2) in a rat archetypal of intraabdominal polymicrobial sepsis, and 3) in a bioterrorism rat archetypal of pneumonic plague. Dr. Wilson afresh accustomed all-embracing acceptance through her adjustment as Editor of the next aggregate of the Handbook of Experimental Pharmacology, “Adenosine Receptors in Health and Disease.”

In contempo NIH/NIAID-funded studies in accord with Saint Louis University, Endacea approved that L-97-1 additional ciprofloxacin administered 72 hours afterwards acknowledgment to Y. pestis, the bacilli amenable for pneumonic plague, provides statistically cogent advance in adaptation and lung anatomy against cipro alone. This abominable archetypal tests the book area terrorists absolution aerosolized Y. pestis in a above airport or alms arrangement or by aerial a crop besom over a amphitheater abounding of people.

“In 1996, Dr. Wilson started up Endacea in the RTP across with a accommodation from the N.C. Biotechnology Center, SBIR allotment from NIH/NIAID, and with abutment from angel investors. In 2006, Endacea accustomed a $75,000 admission from the One North Carolina Small Business Innovation Research Matching Funds Program to bout the Company’s $925,000 SBIR Phase I biodefense grant,” said Don Wilson, the CEO of Endacea.

“When you are application retirement accumulation to advice move avant-garde technology to the patients who charge it, even a baby admission or accommodation is badly accessible in acknowledging operations while the Company attracts added basic based on accurate success. I attending advanced to answer how Endacea fits into the bread-and-butter development account of the RTP economy,” Wilson added.

Mr. Wilson accustomed his AB in Economics from Yale University, his MBA from Harvard Business School and his JD from Harvard Law School. He is a affiliate of the Bar in North Carolina. In accession to managing Endacea, Wilson is a affiliate of the Executive Committee of The Atlantis Group, a affiliate managed angel broker adventure basic fund.

“Part of the argumentation of captivation the RTP Tech Event is to accord able companies, like Endacea, a belvedere for anecdotic their articles and for accepting the basic that they charge to abide their analysis and development,” said Tom Vass, the investment adviser who organizes the Tech Event.

The RTP Tech Event is an addition accord arrangement of companies from the 9 top tech accomplishment amount chains in the RTP bounded economy. Each month, bounded admiral from two altered automated sectors present their thoughts on technology, addition and new artefact development from their own industry, in an accomplishment to activate account for technology crossover amid bounded accomplishment sectors.

After the two presentations, the attic is accessible for altercation about means to advance the bounded economy, to begin for account on artefact innovation, and for means to advance bounded companies. At the end of anniversary session, the attic is accessible for a beginning administrator or artist to angle up and accord a 5 minute elevator angle on his or her venture. “We alarm this befalling “Your Five Minutes of Fame at Goodnight’s,” said Vass.

Registration for the account accident is accessible at MeetUp.com. Annual associates in the RTP Tech Event is $50, and there is a $10 aperture fee that includes the acquirement of the aboriginal alcohol and a abatement on the ball appearance that night at Goodnight’s.

About Endacea, Inc.
Endacea is developing a alternation of proprietary A1 adenosine receptor antagonists as biologic candidates for asthma, sepsis, and added anarchic diseases and as bigger diuretics for patients with congestive affection abortion and renal impairment. Endacea has aswell patented the use of P2X purinoceptor antagonists to amusement disorders that aftereffect in fibrosis and sclerosis, e.g. rheumatoid arthritis, and added indications. The Company’s growing apparent acreage includes 15 issued and 11 awaiting U.S. patents and 18 issued or accustomed all-embracing patents. For added information, see http://www.endacea.com, or acquaintance Don Wilson. dwilson@endacea.nctda.org, 919-406-1888 x1400.

About the RTP Tech Event @ Goodnights. Our event's mission is to actualize added business for bounded firms and to access the amount of new artefact development in the RTP bounded economy. We alarm this "new business abstraction brainstorming." Each month, admiral from bounded accomplishment firms, artefact development engineers and humans with new business account for new articles get calm to begin account for what types of new articles may be acknowledged in the RTP market. The accident is captivated at Goodnight’s Comedy Club, amid at 861 West Morgan St in Raleigh. http://newtech.meetup.com/115/ Contact Tom Vass tvass@privatecapitalmarket.com 919 9754856.

No comments:

Post a Comment